SCHEMBL5751027

SCHEMBL5751027

N/N=C1\C(=O)Nc2cc(Cl)ccc21

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES1 P23141 2/20 0.61
CA1 P00915 4/20 0.48
CA2 P00918 4/20 0.48
TGM2 P21980 1/20 0.47
PPOX P50336 1/20 0.47
GALR3 O60755 1/20 0.46
IDO1 P14902 1/20 0.46
LRRK2 Q5S007 3/20 0.46
CHEK1 O14757 1/20 0.45
TUBB4A P04350 1/20 0.44
TUBB P07437 1/20 0.44
TUBA3C P0DPH7 1/20 0.44
TUBA1B P68363 1/20 0.44
TUBA4A P68366 1/20 0.44
TUBB4B P68371 1/20 0.44
TUBB3 Q13509 1/20 0.44
TUBB2A Q13885 1/20 0.44
TUBB8 Q3ZCM7 1/20 0.44
TUBA3E Q6PEY2 1/20 0.44
TUBA1A Q71U36 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21999924 0.86 CA1 (0.62) CES1CA1CA2TGM2IDO1
SCHEMBL23647047 0.86 CA1 (0.62) CES1CA1CA2TGM2IDO1
SCHEMBL8912592 0.86 CA1 (0.62) CES1CA1CA2TGM2IDO1
SCHEMBL7049823 0.77 CES1 (0.67) CES1CA1CA2TGM2PPOX
SCHEMBL7049827 0.77 CES1 (0.67) CES1CA1CA2TGM2PPOX
SCHEMBL17533489 0.76 CES1 (0.53) CES1CA1CA2TGM2PPOX
SCHEMBL29494851 0.76 CES1 (1.00) CES1TGM2PPOXCHEK1
SCHEMBL624085 0.76 CES1 (1.00) CES1TGM2PPOXCHEK1
SCHEMBL8872987 0.76 CES1 (0.65) CES1CA1CA2TGM2PPOX
SCHEMBL8872979 0.76 CES1 (0.65) CES1CA1CA2TGM2PPOX

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1644362-A2 INDOLINONE HYDRAZIDES AS C-MET INHIBITORS Sugen, Inc. (US) 2006-04-12 EP disclosed
US-20060009493-A1 Indolinone hydrazides as c-Met inhibitors SUGEN, INC. 2006-01-12 US disclosed
WO-2005005378-A2 INDOLINONE HYDRAZIDES AS C-MET INHIBITORS SUGEN, INC. (US) 2005-01-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060009493-A1 Indolinone hydrazides as c-Met inhibitors MET, IGF1R, ROS1 CES1 1061/4885CA1 2666/4885CA2 1116/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.